Merck (NYSE: MRK) reported Q3 EPS of $1.75, $0.20 better than the analyst estimate of $1.55. Revenue for the quarter came in at $13.2 billion versus the consensus estimate of $12.33 billion.

GUIDANCE:

Merck sees FY2021 EPS of $5.65-$5.70, versus the consensus of $5.77. Merck sees FY2021 revenue of $47.4-47.9 billion, versus the consensus of $48.16 billion.

For earnings history and earnings-related data on Merck (MRK) click here.